The Nrf2-Keap1 signaling cascade has generated immense excitement over the last several years as progress has occurred with clinical trials of potential Nrf2 activators stemming from preclinical studies and research that has emerged as promising for patients with neurodegenerative disorders, multiple sclerosis, and psychiatric disorders. This evidence concerns the gene NFE2L2 and psychiatric disorder.